Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | RARG | P13631 | 13/20 | 0.46 |
| ▸ | RXRA | P19793 | 12/20 | 0.46 |
| ▸ | RARB | P10826 | 11/20 | 0.46 |
| ▸ | RARA | P10276 | 10/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733982 | 1.00 | CYP3A4 (0.49) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL6730316 | 0.91 | CYP3A4 (0.49) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL6730317 | 0.91 | CYP3A4 (0.49) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL7771294 | 0.89 | RARG (0.57) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL7771292 | 0.89 | RARG (0.57) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL7769560 | 0.80 | RARG (0.57) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL7769562 | 0.80 | RARG (0.57) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL2788640 | 0.79 | CYP3A4 (0.70) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL6733878 | 0.79 | CYP3A4 (0.71) | CYP3A4RARGRXRARARBRARA | |
| SCHEMBL6734034 | 0.79 | RXRA (0.48) | CYP3A4RARGRXRARARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | DIAZ PHILIPPE (FR) | 2004-08-19 | — | — | US | disclosed |
| US-6030952-A | AS HUMAN AND VETERINARY MEDICINE, PARTICULARLY IN THE TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGIC CONDITIONS, AND IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (FR) | 2000-02-29 | — | — | US | disclosed |
| US-5981776-A | FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | TYR, MITF, CYP1B1 | CYP3A4 147/4885RARG 576/4885RXRA 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.